Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Yosuke Igarashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1998-8074; OpenAlex author ID A5089211597, A5124936147. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 4 papers

Papers 9

  1. Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens. Co-author DOI 10.1007/s00535-026-02447-9↗
  2. Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. Co-author DOI 10.1016/j.ebiom.2026.106137↗
  3. Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20340-w↗
  4. ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20399-5↗
  5. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  6. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002416↗
  7. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095↗
  8. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  9. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 7 shared papers, 2023–2026 · strength 1.61
  2. Yoshihiro Shirai · 6 shared papers, 2023–2026 · strength 1.39
  3. Yoshiaki Tanji · 6 shared papers, 2023–2026 · strength 1.38
  4. Koichiro Haruki · 5 shared papers, 2024–2026 · strength 1.22
  5. Kenei Furukawa · 5 shared papers, 2023–2026 · strength 1.18
  6. Mitsuru Yanagaki · 5 shared papers, 2023–2026 · strength 1.17
  7. Shinji Onda · 4 shared papers, 2023–2025 · strength 0.85
  8. Tomohiko Taniai · 3 shared papers, 2025–2026 · strength 0.79
  9. Michinori Matsumoto · 3 shared papers, 2023–2025 · strength 0.60
  10. Taro Sakamoto · 2 shared papers, 2024–2025 · strength 0.45
  11. Norimitsu Okui · 2 shared papers, 2024–2025 · strength 0.43
  12. Daisuke Ban · 2 shared papers, 2025–2026 · strength 0.42
  13. Kentaro Umemura · 2 shared papers, 2025–2026 · strength 0.42
  14. Shinji Tanaka · 2 shared papers, 2025–2026 · strength 0.42
  15. Masashi Tsunematsu · 2 shared papers, 2023–2025 · strength 0.39
  16. Kyohei Abe · 2 shared papers, 2023–2025 · strength 0.39
  17. Ryoga Hamura · 2 shared papers, 2023–2025 · strength 0.39
  18. Kumiko Umemoto · 1 shared paper, 2026 · strength 0.23
  19. Kazunari Nakahara · 1 shared paper, 2026 · strength 0.23
  20. Hiroyuki Takeda · 1 shared paper, 2026 · strength 0.23
  21. Tomoko Norose · 1 shared paper, 2026 · strength 0.23
  22. Yu Sunakawa · 1 shared paper, 2026 · strength 0.23
  23. Junki Koike · 1 shared paper, 2026 · strength 0.23
  24. Yuki Mochida · 1 shared paper, 2026 · strength 0.22
  25. Tadashi Uwagawa · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.